癌变·畸变·突变 ›› 2022, Vol. 34 ›› Issue (4): 289-294,326.doi: 10.3969/j.issn.1004-616x.2022.04.008

• 论著 • 上一篇    

FIB、FAR和血清肿瘤标记物联合检测在ESCC患者诊断及其临床进展中的意义

崔雯瑄1, 焦文静1, 赵薇1, 杜彦艳1, 田国2, 张金艳1, 马鸣1   

  1. 1. 河北医科大学第四医院检验科, 河北 石家庄 050011;
    2. 河北医科大学第四医院病案室, 河北 石家庄 050011
  • 收稿日期:2021-12-06 修回日期:2022-02-23 发布日期:2022-08-05
  • 通讯作者: 马鸣
  • 作者简介:崔雯瑄,E-mail:cwx1910@126.com。
  • 基金资助:
    河北省财政厅政府资助临床医学优秀人才课题(冀财预复[2020]397号);河北省三三三人才工程资助课题(A20203003);河北省医学科学研究课题(20201094)

Clinical values of combined FIB, FAR and serum tumor markers in diagnosis and progression of ESCC patients

CUI Wenxuan1, JIAO Wenjing1, ZHAO Wei1, DU Yanyan1, TIAN Guo2, ZHANG Jinyan1, MA Ming1   

  1. 1. Department of Clinical Laboratory, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
    2. Record Room, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
  • Received:2021-12-06 Revised:2022-02-23 Published:2022-08-05

摘要: 目的:探讨纤维蛋白原(FIB)、纤维蛋白原与白蛋白比值(FAR)和血清肿瘤标记物联合检测在食管鳞状细胞癌(ESCC)患者诊断及其临床进展中的意义。方法:选取2018年4月—2021年10月河北医科大学第四医院收治的66例ESCC患者,作为ESCC组。收集ESCC患者初诊时的临床病理资料及血常规、凝血功能、生化、血清肿瘤标记物包括癌胚抗原(CEA)和鳞状细胞癌抗原(SCCAg)等相关实验室检测指标。另选取无良恶性肿瘤、心血管等疾病的相对健康志愿者30例,作为对照组。比较两组患者各指标的差异,并分析不同TNM分期中各指标的表达水平,制作ROC曲线评价FIB、FAR、CEA和SCC-Ag对ESCC临床进展的价值;分析其与ESCC患者临床病理指标之间的相关性。结果:ESCC组FIB、FAR、纤维蛋白原与前白蛋白比值(FPR)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)等指标的水平明显高于对照组(P<0.05);III~IV期FIB、FAR、CEA和SCC-Ag水平明显高于I~II期,同时,ROC曲线显示其对ESCC临床进展均具有预测价值(P<0.05),且四者联合检测对ESCC临床进展具有更高的诊断价值;FIB、FAR、SCC-Ag高值组(以ROC曲线得到的cut off值为界值)患者N分期和TNM分期均明显高于低值组(P<0.05);FAR高值组患者的肿瘤最大直径和T分期也明显高于低值组(P<0.05);CEA高值组患者TNM分期明显高于低值组,男性多于女性(P<0.05)。结论:血浆FIB、FAR和血清CEA、SCC-Ag水平与ESCC诊断和临床进展密切相关,与单独检测血清肿瘤标记物相比,四者联合检测用于预测ESCC的临床进展效能更好,值得临床推广使用。

关键词: 纤维蛋白原, 纤维蛋白原与白蛋白比值, 血清肿瘤标记物, 食管鳞状细胞癌, 肿瘤进展

Abstract: OBJECTIVE: To investigate significance of fibrinogen (FIB), fibrinogen to albumin ratio (FAR) and serum tumor markers in the diagnosis and clinical progression of esophageal squamous cell carcinoma (ESCC). METHODS: Sixty-six ESCC patients who were admitted to the Fourth Hospital of Hebei Medical University from April 2018 to October 2021 were selected as the ESCC group. Clinicopathological data and laboratory test indexes of these patients at initial diagnosis were collected. Clinicopathological data,blood routine, coagulation function, biochemistry, serum tumor markers[including Carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC-Ag)] and other laboratory test indicators were collected at the time of initial diagnosis of ESCC patients. Another 30 healthy patients without benign and malignant tumors and cardiovascular diseases were selected as the control group. The differences among indicators between the two groups were compared,and expression levels of different results in different TNM stages were analyzed, and ROC curves was made to evaluate the predictive value of FIB, FAR, CEA and SCC- Ag for clinical propression of EXCC. Correlations between these indicators and clinicopathological features were analyzed. RESULTS: FIB, FAR, ratios of fibrinogen to prealbumin (FPR), ratios of neutrophil to lymphocyte (NLR) NLR and ratios of platelets to lymphocytes (PLR) in the ESCC group were significantly higher than those in the control group (P<0.05). The levels of FIB, FAR, CEA and SCC-Ag in stage III-IV were significantly higher than those in stage I-II. Meanwhile, ROC curves showed that FIB, FAR, CEA and SCC-Ag had predictive values for the clinical progression of ESCC (P<0.05),and combined detection of the four had higher diagnostic value for the clinical progress of ESCC. N stage and TNM stage in high FIB,FAR and SCC-Ag groups (which is object to the cut off value of ROC curve) were significantly higher than those in the low FIB,FAR and SCC-Ag groups (P<0.05). The maximum tumor diameters and T stages of patients with high FAR values were also significantly higher than those of patients with low values (P<0.05). TNM stages of patients with high CEA values were significantly higher than that of patients with low values, and male patients were more than female patients (P<0.05). CONCLUSION: Levels of plasma FIB,FAR,and serum CEA,SCC-Ag were closely related to the diagnosis and clinical progress of ESCC. Compared with detection of tumor markers in serum alone,the combined detection of the four methods showed better clinical efficacy in differentiating the clinical progress of ESCC,therefore,they are worthy of clinical applications.

Key words: FIB, FAR, serum tumor markers, esophageal squamous cell carcinoma, tumor progression

中图分类号: